Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
July 13, 2021 08:15 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
July 12, 2021 08:15 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that...
Brooklyn ImmunoTherapeutics Reports Inducement Grants
July 06, 2021 17:57 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that...
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
June 14, 2021 07:30 ET
|
Brooklyn Immunotherapeutics LLC
NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene...
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index
June 09, 2021 07:30 ET
|
Brooklyn Immunotherapeutics LLC
BROOKLYN, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and...